DTRM BIOPHARMA
Biopharma company conducting clinical trials for cancer research.
DTRM BIOPHARMA
Industry:
Biopharma Biotechnology Medical Pharmaceutical
Founded:
2011-11-11
Address:
Hangzhou, Zhejiang, China
Country:
China
Total Employee:
1+
Status:
Active
Total Funding:
60 M USD
Similar Organizations
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Current Employees Featured
Wei He Founder, President & CEO @ DTRM Biopharma
Founder, President & CEO
Founder
Investors List
Green Pine Capital Partners
Green Pine Capital Partners investment in Series A - DTRM Biopharma
Advantech Capital
Advantech Capital investment in Series A - DTRM Biopharma
More informations about "DTRM Biopharma"
DTRM Biopharma - Crunchbase Company Profile & Funding
Organization. DTRM Biopharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Biopharma company conducting …See details»
DTRM Biopharma - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Jan 3, 2018: Series A - DTRM …See details»
DTRM Biopharma - PitchBook
DTRM Biopharma General Information Description. Conductor of clinical trails and developer of oral doublet and triplet therapy technologies. The company is developing a new drug called DTRMWXHS-12, enabling further medical and …See details»
DTRM Biopharma - Products, Competitors, Financials, Employees ...
DTRM Biopharma's latest funding round is Private Equity. How much did DTRM Biopharma raise? DTRM Biopharma raised a total of $61.2M. Who are the investors of DTRM Biopharma? …See details»
Zhejiang DTRM Biopharma LLC - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Zhejiang DTRM Biopharma LLC of Plymouth Meeting, PA. Get the latest business insights from Dun & …See details»
Zhejiang DTRM Biopharma LLC | Life Sciences PA - Default Site
Zhejiang DTRM Biopharma LLC. Categories. Pharmaceutical. About. Zhejiang DTRM Biopharma LLC is a clinical stage biopharma company focusing on the development of patent-protected …See details»
Zhejiang DTRM Biopharma Co. Ltd. - synapse.zhihuiya.com
Scope of the Follicular Lymphoma Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical …See details»
DTRM Biopharma
DTRM Biopharma is a clinical-stage biopharmaceutical company developing first-in-class, fixed-dose combination (FDC), low dose, oral therapies to treat cancers and immune diseases …See details»
DTRM Biopharma - Contacts, Employees, Board Members
Biopharma company conducting clinical trials for cancer research.See details»
Organization | Zhejiang DTRM Biopharma
Organization Overview. First Clinical Trial. 2016 NCT02900716. First Marketed Drug. None First NDA Approval. None Last Known Activity ... Zhejiang DTRM Biopharma Active Ingredients. …See details»
Zhejiang DTRM Biopharma Co. Ltd.:Company Profile & Technical …
Zhejiang DTRM Biopharma Co. Ltd. is a company that provides Bruton's tyrosine kinase, Drug, Medicine and more. Zhejiang DTRM Biopharma Co. Ltd. is headquartered in China Zhejiang …See details»
Zhejiang DTRM Completes $60 Million A Round for US-China …
Zhejiang DTRM Biopharma announced a $60 million Series A round that will support clinical trials of its lead cancer candidate, a Bruton’s tyrosine kinase (BTK) inhibitor. The candidate is …See details»
Patents Assigned to Zhejiang DTRM Biopharma Co. Ltd.
Oct 26, 2018 Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical …See details»
BioCentury - DTRM Biopharma closes series A round
Jan 5, 2018 Zhejiang DTRM Biopharma Co. Ltd. (Zhejiang, China) raised a series A round on Jan. 2 worth more than $60 million, with components in two currencies. The round included a …See details»
AZD-5492 - Drug Targets, Indications, Patents - Synapse
Mar 8, 2025 LAS VEGAS, Nov. 28, 2024 /PRNewswire/ -- DelveInsight's ' Follicular Lymphoma Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline follicular …See details»
A New Trispecific Antibody for CLL on the Horizon - CLL Society
Jan 17, 2021 DTRMWXHS-12 (DTRM-12) is a new BTK inhibitor developed by Zhejiang DTRM Biopharma Company, Ltd of China. DTRM-12 is the “backbone” of therapy given at a “low …See details»
Real-world prognostic testing and treatment patterns in CLL/SLL ...
A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS ... and TG Therapeutics; has received research funding from AbbVie, …See details»
Artiva Biotherapeutics, Inc. (Artiva Biotherapeutics, Inc.) - 药物管 …
He is currently the interim Chief Development Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at Johnson & Johnson (Janssen/Centocor) (J & J) most recently as the Vice …See details»
Pacylex Pharmaceuticals, Inc. (Pacylex Pharmaceuticals, Inc.) - 药物 …
LAS VEGAS, Nov. 28, 2024 /PRNewswire/ -- DelveInsight's ' Follicular Lymphoma Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline follicular lymphoma …See details»
Conjupro Biotherapeutics, Inc. (Conjupro Biotherapeutics, Inc.) - 药 …
了解Conjupro Biotherapeutics, Inc. (Conjupro Biotherapeutics, Inc.)公司的药物管线，治疗领域，技术平台，以及它的8项临床试验, 3篇新闻，疾病领域:肿瘤，内分泌与代谢疾病，神经系统 …See details»